We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
730 hedge funds and large institutions have $14.1B invested in Neurocrine Biosciences in 2025 Q4 according to their latest regulatory filings, with 138 funds opening new positions, 279 increasing their positions, 220 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
237% more first-time investments, than exits
New positions opened: 138 | Existing positions closed: 41
27% more repeat investments, than reductions
Existing positions increased: 279 | Existing positions reduced: 220
12% more funds holding
Funds holding: 649 → 730 (+81)
1.48% more ownership
Funds ownership: 98.01% → 99.49% (+1.5%)
3% more capital invested
Capital invested by funds: $13.6B → $14.1B (+$441M)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
42% less call options, than puts
Call options by funds: $41.3M | Put options by funds: $71.6M
Holders
730
Holders Change
+81
Holders Change %
+12.48%
% of All Funds
8.88%
Holding in Top 10
10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-9.09%
% of All Funds
0.12%
New
138
Increased
279
Reduced
220
Closed
41
Calls
$41.3M
Puts
$71.6M
Net Calls
-$30.3M
Net Calls Change
+$4.3M
Top Buyers
| 1 |
Two Sigma Advisers
New York
|
+$101M |
| 2 |
Two Sigma Investments
New York
|
+$92.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$89.7M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$72.2M |
| 5 |
JP Morgan Chase
New York
|
+$68.1M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$144M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$103M |
| 3 |
Morgan Stanley
New York
|
-$89.5M |
| 4 |
Millennium Management
New York
|
-$77.4M |
| 5 |
Jennison Associates
New York
|
-$73M |
